Start with the neuron
Cognitive impairment is ultimately a loss of neuronal function. Casp-Aid is pursuing a differentiated approach designed to address the cellular processes that disrupt neuronal structure and function.
Focused on the NLRP1–Caspase-1–Caspase-6 neurodegenerative pathway.
THE SCIENCE
A pathway connected to cognitive decline
The NLRP1 Inflammasome–Caspase-1–Caspase-6 Axis
- Initiated by various stressors
- Causes neuronal damage
- Associated with cognitive impairment
OUR LEAD PROGRAM: CIM765
Targeting Caspase-1 to protect neuronal function
CIM765 is a potentially first-in-class, potent and selective Caspase-1 inhibitor. In preclinical models, it restored cognition and neuronal connectivity, even at advanced stages of pathology.
Targeted
Potent & highly selective Caspase-1 inhibitor.
Reaches the Brain
Active metabolite detected in hippocampus and cortex in preclinical studies, at levels sufficient to inhibit Caspase-1.
Established Human Safety Data
Studied in more than 300 participants across Phase I and Phase II trials, including up to 9 months of continuous dosing.
Newly Identified Therapeutic Rationale
Patents protecting its use for cognitive impairment.